|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Arai, Hiroyuki; Millstein, Joshua; Yang, Yan; Stintzing, Sebastian; Wang, Jingyuan; Battaglin, Francesca; Kawanishi, Natsuko; Jayachandran, Priya; Soni, Shivani; Zhang, Wu; Heinemann, Volker und Lenz, Heinz-Josef
(2022):
Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
In: Clinical Colorectal Cancer, Bd. 21, Nr. 3: S. 259-266
Wang, Jingyuan; Xiao, Yi; Loupakis, Fotios; Stintzing, Sebastian; Yang, Yan; Arai, Hiroyuki; Battaglin, Francesca; Kawanishi, Natsuko; Jayachandran, Priya; Soni, Shivani; Zhang, Wu; Mancao, Christoph; Cremolini, Chiara; Liu, Tianshu; Heinemann, Volker; Falcone, Alfredo; Shen, Lin; Millstein, Joshua und Lenz, Heinz-Josef
(2022):
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
In: European Journal of Cancer, Bd. 172: S. 22-30
Arai, Hiroyuki; Cao, Shu; Battaglin, Francesca; Wang, Jingyuan; Kawanishi, Natsuko; Tokunaga, Ryuma; Loupakis, Fotios; Stintzing, Sebastian; Soni, Shivani; Zhang, Wu; Mancao, Christoph; Salhia, Bodour; Mumenthaler, Shannon M.; Cremolini, Chiara; Heinemann, Volker; Falcone, Alfredo; Millstein, Joshua und Lenz, Heinz-Josef
(2021):
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC.
In: Molecular Cancer Therapeutics, Bd. 20, Nr. 6: S. 1153-1160
Arai, Hiroyuki; Millstein, Joshua; Loupakis, Fotios; Stintzing, Sebastian; Wang, Jingyuan; Battaglin, Francesca; Kawanishi, Natsuko; Jayachandran, Priya; Soni, Shivani; Zhang, Wu; Mumenthaler, Shannon M.; Cremolini, Chiara; Heinemann, Volker; Falcone, Alfredo und Lenz, Heinz-Josef
(2021):
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
In: European Journal of Cancer, Bd. 150: S. 133-142